Author(s)

Ayala Yahav¹, Chaim Kaplinsky², Miguel M. Glatstein^3*, Yaakov Shachter¹, Aryeh Simmonds¹, Yakov Shiff¹, Dennis Scolnik⁴, Nechama Sharon^1,5

¹Department of Pediatrics, Laniado Hospital, Netanya, Israel.
²Department of Pediatric Hemato-Oncology, Sheba Hospital, Tel Hashomer, Israel.
³Divisions of Pediatric Emergency Medicine and Clinical Pharmacology and Toxicology, Dana-Dwek Children Hospital, Tel Aviv Sourasky Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel Aviv, Israel.
⁴Divisions of Pediatric Emergency Medicine and Clinical Pharmacology and Toxicology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
⁵Pediatric Hemato-Oncology, Laniado Hospital, Netanya, Israel.

Background: Iron deficiency anemia in infants is the most common micronutrient deficiency worldwide. The main cause is low iron intake in the presence of accelerated physiologic growth rate. Objective: The current study aimed at prospectively comparing the efficacy of iron III hydroxide polymaltose syrup (IPS) versus iron III hydroxide polymaltose drops (IPD) in treating iron deficiency among infants attending the hematology outpatient clinic. Our hypothesis was that IPS would be less effective possibly related to the difficulty of giving the medication. Methods: Participants diagnosed with iron deficiency anemia between 11-24 months were randomly assigned to receive either IPS or IPD for 3 months. The main outcome parameter was hemoglobin blood level, while the secondary outcome parameters were: 1) iron; 2) ferritin; 3) transferrin (i.e. total iron binding capacity); 4) mean corpuscular volume; and 5) red blood cell distribution width. Results: Out of the 104 recruited infants, 55 (52%) completed the study: 29 in the IPS group and26 inthe IPD group. There was no significant difference in the main outcome parameter at either 1 or 3 months of treatment: mean hemoglobin was 10.5 versus 10.7 g/dL within a 1 month treatment, P = 0.4; mean hemoglobin was 11.0 versus 11.1 g/dL within a 3 months of treatment, P = 0.59. Likewise, no significant differences were found with respect to the occurrence of side effects. Conclusion: Oral IPD and IPS are equally effective in treating iron deficiency anemia in infants aged 11 - 24 months.

Iron Deficiency Anemia (IDA), Treatment, Iron III Hydroxide Polymaltose, Formulation

Yahav, A. , Kaplinsky, C. , Glatstein, M. , Shachter, Y. , Simmonds, A. , Shiff, Y. , Scolnik, D. and Sharon, N. (2015) Syrup versus Drops of Iron III Hydroxide Polymaltose in the Treatment of Iron Deficiency Anemia of Infancy. Open Journal of Pediatrics, 5, 34-38. doi: 10.4236/ojped.2015.51007.